首页> 中国专利> 一种突变的人肿瘤坏死因子相关凋亡诱导配体多肽及其用途

一种突变的人肿瘤坏死因子相关凋亡诱导配体多肽及其用途

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明提供了一种突变的人肿瘤坏死因子相关的凋亡诱导配体(TRAIL)的cDNA序列和由该序列编码的多肽。本发明的多肽具有快速诱导肿瘤细胞凋亡性死亡的作用。

著录项

公开/公告号CN1172956C

专利类型发明授权
公开/公告日2004-10-27

原文格式PDF
申请/专利权人成都地奥制药集团有限公司;
展开▼

申请/专利号CN01105946.X
发明设计人李伯刚;高小平;刘忠荣;
展开▼

申请日2001-04-10
分类号C07K14/525;C12N15/63;A61P35/00;
代理机构31213 上海新天专利代理有限公司;
代理人王巍
地址 610041 四川成都高新区高新大道创业路26号
入库时间 2022-08-23 08:57:02

法律信息

法律状态公告日

法律状态信息

法律状态
2009-05-27

专利申请权、专利权的转移(专利权的转移) 变更前: 变更后: 登记生效日:20090417 申请日:20010410

专利申请权、专利权的转移(专利权的转移)
2004-10-27

授权

授权
2003-02-12

实质审查的生效

实质审查的生效
2003-01-29

实质审查的生效

实质审查的生效
2002-11-20

公开

公开
2001-10-10

实质审查的生效

实质审查的生效

查看全部

相似文献

专利
中文文献
外文文献

1. 一种突变的人肿瘤坏死因子相关凋亡诱导配体多肽及其用途 [P] . 中国专利： CN1172956C . 2004.10.27
2. 一种改构的人淀粉样多肽突变体-普兰林肽(pramlintide)的制备方法 [P] . 中国专利： CN101413009B . 2011.05.04
3. Procedure for the in vitro production of polypeptides muteinas eukaryotic in vitro; procedure for obtaining a human cell that expresses a muteina a polypeptide Human Target. Human cell obtainable by Said method and use of said human cell [P] . AR068104A2 . 2009-11-04

机译：体外真核多肽突变体的体外生产方法;获得表达突变体多肽人靶标的人细胞的方法。可通过所述方法获得的人细胞及其用途
4. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症
5. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066